Larimar Therapeutics, Inc.
$4.81
▲
2.35%
2026-04-21 07:58:01
www.larimartx.com
NGM: LRMR
Explore Larimar Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$499.68 M
Current Price
$4.81
52W High / Low
$6.42 / $1.73
Stock P/E
—
Book Value
$0.94
Dividend Yield
—
ROCE
-212.84%
ROE
-1.33%
Face Value
—
EPS
$-2.27
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
71
Beta
1.02
Debt / Equity
5.21
Current Ratio
2.19
Quick Ratio
2.19
Forward P/E
-2.69
Price / Sales
—
Enterprise Value
$371.05 M
EV / EBITDA
-2.15
EV / Revenue
—
Rating
Strong Buy
Target Price
$16.7
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | OmniAb, Inc. | $1.55 | — | $237.44 M | — | -24.23% | -23.36% | $2.29 / $1.22 | $1.85 |
| 2. | Hoth Therapeutics, Inc. | $0.74 | — | $13.96 M | — | -200.97% | -1.91% | $2.12 / $0.49 | $0.4 |
| 3. | Kalaris Therapeutics, Inc. | $6.6 | — | $132.49 M | — | -41.2% | -3.08% | $11.88 / $2.14 | $3.44 |
| 4. | Enveric Biosciences, Inc. | $3.65 | — | $3.44 M | — | -210.04% | -3.04% | $17.84 / $1.71 | $3.94 |
| 5. | Silo Pharma, Inc. | $0.67 | — | $8.38 M | — | -61.55% | -74.57% | $1.19 / $0.22 | $0.47 |
| 6. | Korro Bio, Inc. | $14.28 | — | $207.54 M | — | -85.99% | -1.11% | $55.89 / $5.2 | $5.46 |
| 7. | MoonLake Immunotherapeutics | $17.89 | — | $1.32 B | — | -64.61% | -60.78% | $62.75 / $5.95 | $4.27 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -64.02 M | -49.5 M | -27.79 M | -31.19 M | -31.29 M |
| Net Profit | -62.5 M | -47.71 M | -26.18 M | -29.28 M | -28.82 M |
| EPS in Rs | -0.6 | -0.46 | -0.25 | -0.28 | -0.28 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -172.5 M | -90.89 M | -41.76 M | -36.53 M |
| Net Profit | -165.67 M | -80.6 M | -36.95 M | -35.35 M |
| EPS in Rs | -1.59 | -0.78 | -0.36 | -0.34 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 145.84 M | 200.22 M | 95.94 M | 126.41 M |
| Total Liabilities | 67.76 M | 28.41 M | 14.21 M | 15.5 M |
| Equity | 78.08 M | 171.81 M | 81.72 M | 110.9 M |
| Current Assets | 142.02 M | 195.3 M | 90.17 M | 120.74 M |
| Current Liabilities | 64.8 M | 24.36 M | 9.51 M | 10.71 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -113.2 M | -70.76 M | -33.46 M | -27.57 M |
| Investing CF | 100.31 M | -85.39 M | 33.35 M | -90.96 M |
| Financing CF | 65.09 M | 161.88 M | 0.03 M | 75.26 M |
| Free CF | -113.29 M | -71.28 M | -33.62 M | -27.67 M |
| Capex | -0.09 M | -0.52 M | -0.16 M | -0.1 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -105.54% | -118.15% | -4.51% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.